Amanta Healthcare Limited (AMANTA) today announced the unaudited financial results for the quarter ended June 30, 2026. The company reported revenue of ₹68.8 crore for Q1FY27, marking a 5.4% year-on-year growth driven by improved product mix and better price realizations. The EBITDA stood at INR 15.2 crore, with margins moderating to 22% from 24% due to higher raw material, employee cost, and other operating expenses. Profitability was impacted by higher finance costs, resulting in a PAT of INR 3.3 crore, a 5.6% decline from INR 3.5 crore in Q1FY26.

Sustained Revenue Growth

The revenue growth was achieved on the existing capacity base, reflecting a robust performance despite the economic challenges. The company’s focus on an improved product mix and better price realizations contributed significantly to this growth.

Operational Performance

Although EBITDA remained stable at INR 15.2 crore, the EBITDA margin declined by 200 basis points to 22% due to increased costs. The company’s operational performance remains resilient, highlighting its ability to manage costs effectively.

Strategic Capacity Expansion

The company is progressing with its capacity expansion plans, with the Steriport plant expected to be commissioned by Q2FY27 and the SVP expansion targeted for Q4 FY27. These initiatives are anticipated to enhance manufacturing capacity, cost efficiency, and operating leverage in the coming years.

Commenting on the performance for the quarter, Bhavesh Patel, Chairman & Managing Director, Amanta Healthcare Limited said, “Q1FY27 marked a period of steady performance for Amanta Healthcare, with revenue standing at ₹68.8 crore, reflecting a growth of 5.4% YoY, driven by an improved product mix and better price realizations. The coming quarters present an exciting growth opportunity as we progress with our capacity expansion plans. The SteriPort facility is expected to be commissioned by Q2FY27, followed by the SVP expansion during Q4 FY27, creating a good headroom for future growth. The captive solar power project will further support cost efficiencies and strengthen our operating profile. With these initiatives progressing well, we are confident of building greater scale, enhancing profitability and unlocking sustainable growth opportunities across both domestic and export markets.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Amanta Healthcare Limited

Amanta Healthcare Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Amanta gains 27.5% over three months and trades near its 52-week highs. D/E reaches 2.14. High leverage in this environment is a material risk the market cannot ignore. Thin margins at 5.2% leave limited room for error — any demand softness or cost spike hits the bottom line hard. The stock trades at 84% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. The stock rises 27.5% in three months. Yet revenue grows at only 3.8% and the PEG stands at 99.00. Either the market prices in a turnaround that has not shown up yet, or this is momentum without substance. Check the next two earnings prints before drawing conclusions. Check Fundamentals of Amanta Healthcare Limited.